ArticleCureus2024
Validation of the Georgian Version of the Multiple Sclerosis Quality of Life-54 (MSQOL-54) Questionnaire for Assessing the Quality of Life in Patients With Multiple Sclerosis.
Article in Cureus, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- The Role of Self-Compassion on Self-Care With the Mediating Role of Illness Perception in Patients With Multiple Sclerosis Referred to Sina Hospital: Based on the Leventhal Model.Brain and behavior · 2026Article
- Cultural decoupling of quality of life in multiple sclerosis patients: a systematic review and psychometric analysis of the MSQOL-54.Acta neurologica Belgica · 2026Review
- Investigating the Psychometric Properties of the Persian Version of the Revised Illness Perception Questionnaire in a Sample of Patients With Multiple Sclerosis.Brain and behavior · 2025Article
- Depression, Anxiety, and MSQOL-54 Outcomes in RRMS Patients Receiving Fingolimod or Cladribine: A Cross-Sectional Comparative Study.Medicina (Kaunas, Lithuania) · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
BACKGROUND AND
objectivesMultiple sclerosis (MS) significantly impacts health-related quality of life (HRQOL). The Multiple Sclerosis Quality of Life-54 (MSQOL-54) is a widely used tool for assessing HRQOL in individuals with MS. Adapting this tool to the local language and culture is essential for ensuring cultural relevance, enabling comprehensive care, and allowing international comparability. This study aims to validate the Georgian version of the MSQOL-54 (MSQOL-54 GEO) and assess HRQOL in MS patients in Georgia. METHODOLOGY: A cross-sectional study was conducted, involving 384 individuals with MS. The MSQOL-54 questionnaire was translated using a forward-backward translation technique. Statistical analysis, performed using SPSS 22.0, included internal consistency reliability measured by Cronbach's alpha coefficient (α) with 95% confidence intervals (95% CI), while external validity was determined through the correlation of individual components and composite scores with the Expanded Disability Status Scale (EDSS).
resultsThe MSQOL-54-GEO demonstrated strong validity and reliability, with most components showing Cronbach's alpha values above 0.70, except for the "Social Function" component. The "Health Perceptions" component recorded the lowest average score (47.3 ± 20.0). Significant correlations were found between MS duration and "Physical Health," as well as "Cognitive Function." CONCLUSIONS AND IMPLICATIONS: The findings indicate that the MSQOL-54-GEO is a reliable, convenient, and accepted tool for assessing HRQOL among MS patients in Georgia. This validation contributes valuable insights into the internal consistency of the MSQOL-54-GEO, facilitating its essential use in clinical practice and research, for evaluating treatment outcomes and guiding holistic care approaches, encompassing physical, emotional, and social well-being.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.